After 12 days, neither combination of ADU-S100 plus anti–PD-1 and anti–CTLA-4 nor ADU-S100 plus anti–CTLA-4 treatments showed a significant difference in tumor volume compared with ADU-S100 alone or ADU-S100 plus anti–PD-1 treatments (Supplemental Figure 8, B and C). The gene discussed is CTLA4; the disease is neoplasm.